| Dr James I Rho, MD | |
|
9327 Fairway View Pl, Suite 210, Rancho Cucamonga, CA 91730-0968 | |
| (909) 758-0411 | |
| (909) 758-0711 |
| Full Name | Dr James I Rho |
|---|---|
| Gender | Male |
| Speciality | Interventional Pain Management |
| Experience | 31 Years |
| Location | 9327 Fairway View Pl, Rancho Cucamonga, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548323769 | NPI | - | NPPES |
| 361322601 | Other | ACS US DEPT OF LABOR | |
| G80002 | Other | CA | MEDICAL LICENSE |
| 330859420 | Other | CA | BLUE CROSS |
| 720000260 | Other | RAILROAD MEDICARE | |
| 00G800020 | Other | CA | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | G80002 (California) | Primary |
| Entity Name | Inland Interventional Medical Associates, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295978427 PECOS PAC ID: 3870643646 Enrollment ID: O20090617000148 |
News Archive
Researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have found new evidence to explain how cholesteryl ester transfer protein (CETP) mediates the transfer of cholesterol from "good" high density lipoproteins (HDLs) to "bad" low density lipoproteins.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Medical students give the U.S. healthcare system a poor grade and consider technology a ‘must have' for their future practice. These opinions and technology priorities, including mobile reference and electronic medical records (EMRs), are represented in the fourth annual Future Physicians of America survey by Epocrates, Inc., the leading provider of mobile medical technology.
A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).
Just as a scientist dressed in a lab coat and goggles might get stuck behind the velvet rope at a trendy bar, many otherwise good drugs can't get inside cells if they don't look the part. In a report published this week in ACS Central Science, researchers report a new set of molecules that could ferry medicines into cells by taking on the right charge and shape, easily sliding past lipid membranes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James I Rho, MD P O Box 11238, San Bernardino, CA 92423-1238 Ph: (909) 758-0411 | Dr James I Rho, MD 9327 Fairway View Pl, Suite 210, Rancho Cucamonga, CA 91730-0968 Ph: (909) 758-0411 |
News Archive
Researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have found new evidence to explain how cholesteryl ester transfer protein (CETP) mediates the transfer of cholesterol from "good" high density lipoproteins (HDLs) to "bad" low density lipoproteins.
Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's.
Medical students give the U.S. healthcare system a poor grade and consider technology a ‘must have' for their future practice. These opinions and technology priorities, including mobile reference and electronic medical records (EMRs), are represented in the fourth annual Future Physicians of America survey by Epocrates, Inc., the leading provider of mobile medical technology.
A national research collaboration of senior researchers, including a researcher from Moffitt Cancer Center, has found that 20 to 25 percent of "heavily pre-treated" patients with a variety of cancers who enrolled in a clinical trial had "objective and durable" responses to a treatment with BMS-936558, an antibody that specifically blocks programmed cell death 1 (PD-1).
Just as a scientist dressed in a lab coat and goggles might get stuck behind the velvet rope at a trendy bar, many otherwise good drugs can't get inside cells if they don't look the part. In a report published this week in ACS Central Science, researchers report a new set of molecules that could ferry medicines into cells by taking on the right charge and shape, easily sliding past lipid membranes.
› Verified 7 days ago